Senthilkumar Alagesan
Overview
Explore the profile of Senthilkumar Alagesan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Byrnes D, Masterson C, Brady J, Alagesan S, Gonzalez H, McCarthy S, et al.
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259300
: Pulmonary sepsis is a leading cause of hospital mortality, and sepses arising from antimicrobial-resistant (AMR) bacterial strains are particularly difficult to treat. Here we investigated the potential of mesenchymal...
2.
Alagesan S, Brady J, Byrnes D, Fandino J, Masterson C, McCarthy S, et al.
Stem Cell Res Ther
. 2022 Feb;
13(1):75.
PMID: 35189962
Cell therapy, particularly mesenchymal stem/stromal (MSC) therapy, has been investigated for a wide variety of disease indications, particularly those with inflammatory pathologies. However, recently it has become evident that the...
3.
Fazekas B, Alagesan S, Watson L, Ng O, Conroy C, Catala C, et al.
Stem Cell Rev Rep
. 2022 Jan;
18(4):1444-1460.
PMID: 35013938
Mesenchymal stromal cells (MSCs) ameliorate pre-clinical sepsis and sepsis-associated acute kidney injury (SA-AKI) but clinical trials of single-dose MSCs have not indicated robust efficacy. This study investigated immunomodulatory effects of...
4.
Targeting stromal cell Syndecan-2 reduces breast tumour growth, metastasis and limits immune evasion
Loftus P, Watson L, Deedigan L, Camarillo-Retamosa E, Dwyer R, OFlynn L, et al.
Int J Cancer
. 2020 Nov;
148(5):1245-1259.
PMID: 33152121
Tumour stromal cells support tumourigenesis. We report that Syndecan-2 (SDC2) is expressed on a nonepithelial, nonhaematopoietic, nonendothelial stromal cell population within breast cancer tissue. In vitro, syndecan-2 modulated TGFβ signalling...
5.
Alagesan S, Sanz-Nogues C, Chen X, Creane M, Ritter T, Ceredig R, et al.
Immunol Cell Biol
. 2018 Feb;
96(5):536-548.
PMID: 29446493
Allogeneic mesenchymal stromal cells (allo-MSC) are a promising "off-the-shelf" therapy with anti-inflammatory and pro-repair properties. This study investigated humoral immune responses to intramuscular (IM) injections of allo-MSC. Total and isotype-specific...
6.
Cigognini D, Gaspar D, Kumar P, Satyam A, Alagesan S, Sanz-Nogues C, et al.
Sci Rep
. 2016 Aug;
6:30746.
PMID: 27478033
Modular tissue engineering is based on the cells' innate ability to create bottom-up supramolecular assemblies with efficiency and efficacy still unmatched by man-made devices. Although the regenerative potential of such...
7.
Duffy M, McNicholas B, Monaghan D, Hanley S, McMahon J, Pindjakova J, et al.
Am J Physiol Renal Physiol
. 2014 Oct;
307(12):F1412-26.
PMID: 25339699
Mesenchymal stem cells (MSCs) suppress T helper (Th)17 cell differentiation and are being clinically pursued for conditions associated with aberrant Th17 responses. Whether such immunomodulatory effects are enhanced by coadministration...
8.
Prado-Lopez S, Duffy M, Baustian C, Alagesan S, Hanley S, Stocca A, et al.
Immunol Cell Biol
. 2014 Apr;
92(7):612-23.
PMID: 24777310
Multipotent mesenchymal stromal cells are multipotent cells capable of differentiating into different mesodermal cell types. Enigmatically, mesenchymal stromal cells present in the bone marrow support early lymphopoiesis yet can inhibit...
9.
Alagesan S, Griffin M
Kidney Int
. 2014 Apr;
85(4):730-3.
PMID: 24682117
Infusing ex vivo-generated alternatively activated macrophages (AAM) has shown promise in experimental systems as a therapeutic strategy for inflammatory kidney disease. In the mouse Adriamycin nephropathy model, however, Cao et...
10.
Alagesan S, Griffin M
Curr Opin Organ Transplant
. 2013 Dec;
19(1):65-72.
PMID: 24370985
Purpose Of Review: Recent developments toward the successful clinical application of autologous and allogeneic mesenchymal stem cells (MSCs) to organ transplantation are summarized with a focus on safety and efficacy....